XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Sees Significant Decline in Short Interest

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 9,750 shares, a decrease of 49.3% from the May 14th total of 19,218 shares. Based on an average trading volume of 26,934 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.6% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, XTL Biopharmaceuticals has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Up 2.3%

NASDAQ:XTLB traded up $0.05 during trading hours on Monday, reaching $2.18. The company had a trading volume of 2,551 shares, compared to its average volume of 1,149,400. The firm has a market cap of $4.80 million, a price-to-earnings ratio of -3.41 and a beta of 1.48. The business’s 50-day simple moving average is $2.54 and its two-hundred day simple moving average is $4.42. XTL Biopharmaceuticals has a twelve month low of $2.01 and a twelve month high of $10.28.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.